There are limited treatment options for patients with advanced cancer. Current therapies include surgery, chemotherapy, and radiation therapy. These treatments are relatively ineffective and have considerable morbidity associated with them. An alternative treatment strategy that has been successful for many melanoma and renal cell carcinoma patients is immunotherapy. So far, immunotherapy has not been well tested in breast and ovarian cancer patients. The major factors which have limited the development of immunotherapy for most cancers is there are the lack of T cell antigens expressed by cancer cells and that the antigens identified so far are poorly immunogenic. One antigen that has been extensively studied as a potential target for immunotherapy for many cancers is the proto-oncogene Her-2/neu. Several groups have reported isolating Her-2/neu reactive T cells that recognize a variety of cancers including breast, colon, and ovarian cancer. However, early clinical trials in patients vaccinated with antigenic Her-2/neu peptides failed to elicit an effective anti-tumor immune response. Since most immunotherapy strategies are totally dependent on boosting the host anti-tumor immune response, attempts to boost the anti-tumor immune response to weakly immunogenic antigens expressed by cancer cells such as Her-2/neu have proven to be ineffective against breast, ovarian, lung, and colon cancer. We have developed an alternative strategy for providing antitumor reactivity to cancer patients which does not require boosting the host anti-tumor immune response. Using retroviral vectors encoding T cell receptor (TCR) genes, we have been able to transfer the specificity of tumor reactive T cell clones to normal peripheral blood T cells. The goal of this proposal is to determine if normal peripheral blood T cells can be engineered to recognize Her-2/neu+ breast, ovarian, lung, and colon cancer cells and to evaluate therapeutic the efficacy of TCR transduced T cells in treating established Her- 2/neu+ tumors in mice. Successful completion of these goals may lead to a new treatment for cancer patients with Her-2/neu+ tumors using autologous TCR gene modified T cells. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA102280-05
Application #
7303118
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Howcroft, Thomas K
Project Start
2003-08-15
Project End
2008-05-31
Budget Start
2006-09-01
Budget End
2007-05-31
Support Year
5
Fiscal Year
2006
Total Cost
$280,412
Indirect Cost
Name
Medical University of South Carolina
Department
Surgery
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Spear, Timothy T; Wang, Yuan; Smith Jr, Thomas W et al. (2018) Altered Peptide Ligands Impact the Diversity of Polyfunctional Phenotypes in T Cell Receptor Gene-Modified T Cells. Mol Ther 26:996-1007
Spear, Timothy T; Wang, Yuan; Foley, Kendra C et al. (2017) Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells. Cancer Immunol Immunother 66:1411-1424
Spear, Timothy T; Callender, Glenda G; Roszkowski, Jeffrey J et al. (2016) TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors. Cancer Immunol Immunother 65:293-304
Spear, Timothy T; Riley, Timothy P; Lyons, Gretchen E et al. (2016) Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability. J Leukoc Biol 100:545-57
McMahan, Rachel H; Golden-Mason, Lucy; Nishimura, Michael I et al. (2010) Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest 120:4546-57
Norell, HÃ¥kan; Martins da Palma, Telma; Lesher, Aaron et al. (2009) Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death. Cancer Res 69:6282-9
Klarquist, Jared; Barfuss, Allison; Kandala, Sridhar et al. (2009) Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells. Am J Pathol 175:2463-72
Moore, Tamson V; Lyons, Gretchen E; Brasic, Natasha et al. (2009) Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition. Cancer Immunol Immunother 58:719-28
Voelkl, Simon; Moore, Tamson V; Rehli, Michael et al. (2009) Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination. Cancer Immunol Immunother 58:709-18
Ando, Takashi; Mimura, Kousaku; Johansson, C Christian et al. (2008) Transduction with the antioxidant enzyme catalase protects human T cells against oxidative stress. J Immunol 181:8382-90

Showing the most recent 10 out of 20 publications